Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Patent
1995-06-07
1997-07-15
Criares, Theodore J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
514650, 514654, 514655, A61K 31135, A61K 3113
Patent
active
056483961
ABSTRACT:
A method and composition are utilizing the pure R(-) isomer of fluoxetine which is a potent antidepressant and appetite suppressant substantially free of adverse effects. In addition, a method and composition are disclosed utilizing the pure R(-) isomer of fluoxetine which is useful to treat migraine headaches, pain, in particular chronic pain, psychoactive substance abuse disorders and obsessive compulsive disorders.
REFERENCES:
patent: 3536809 (1970-10-01), Applezweig
patent: 3598123 (1971-08-01), Zaffaroni
patent: 3630200 (1971-12-01), Higuchi
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 4008719 (1977-02-01), Theeuwes et al.
patent: 4018895 (1977-04-01), Molloy et al.
patent: 4194009 (1980-03-01), Molloy et al.
patent: 4313896 (1982-02-01), Molloy et al.
patent: 4314081 (1982-02-01), Molloy et al.
patent: 4329356 (1982-05-01), Holland
patent: 4444778 (1984-04-01), Coughlin
patent: 4590213 (1986-05-01), Stark
patent: 4594358 (1986-06-01), Hynes
patent: 4596807 (1986-06-01), Crosby
patent: 4626549 (1986-12-01), Molloy et al.
patent: 4647591 (1987-03-01), Cherkin et al.
patent: 4698342 (1987-10-01), Crosby
patent: 4777173 (1988-10-01), Shrotryia et al.
patent: 4797286 (1989-01-01), Thakkar et al.
patent: 4847092 (1989-07-01), Thakkar et al.
patent: 4868344 (1989-09-01), Brown
patent: 4895845 (1990-01-01), Seed
patent: 4918207 (1990-04-01), Brown
patent: 4918242 (1990-04-01), Brown
patent: 4918246 (1990-04-01), Brown
Carccia et al., "Influence of Dose and Route of Administration on the Kinetics of Fluoxetine and its Metabolite Norfluoxetine in the Rat", Psychopharmacology, 100: 509-514 (1990).
Teicher et al., "Emergence of Intense Suicidal Precoccupation During Fluoxetine Treatment", Am. J. Psychiatry, 147(2): 207-210 (1990).
Wong et al., "Fluoxetine and Its Two Enantiomers as Selective Serotonin Uptake Inhibitors", Acts Pharm. Nord., 2(3): 171-180 (1990).
Corey and Reichard, "Enantioselective and Practical Syntheses of R-and S-Fluoxetines", Tetrahedron Lett., 30(39): 5207-5210 (1989).
Coutts and Baker, "Implications of Chirality and Geometric Isomerism in Some Psychoactive Drugs and Their Metabolites", Chirality, 1: 99-120 (1989).
Coutts and Baker, "Metabolic Implications of Chiral Centers in Psychotropic Drugs", Prog. Neuro-Psychopharmacol. & Biol. Psychiat., 13: 405-417 (1989).
Jamali et al., "Enantioselective Aspects of Drug Action and Disposition: Therapeutic Pitfalls", J. Pharm. Sci. 78(9): 695-715 (1989).
Gao and Sharples, "Asymmetric Synthesis of Both Enantiomers of Tomoxetine and Fluoxetine. Selective Reduction of 2,3-Epoxycinnamyl Alcohol with Red-Al", J. Org. Chem.,53(17): 4081-4084 (1988).
Kim and Wurtman, "Selective Effects of CGS 0686B, d1-Fenfluramine or Fluoxetine on Nutrient Selection", Physiology & Behavior, 42: 319-322 (1988).
Robertson et al., "Absolute Configurations and Pharmacological Activities of the Optical Isomers of Fluoxtine, a Selective Serotonin-Uptake Inhibitor", J. Med. Chem., 31: 1412-1417 (1988).
Wong et al., "Suppression of Food Intake in Rat by Fluoxetine: Comparison of Enantiomers and Effects of Serotonin Antagonists", Pharmacology Biochemistry & Behavior, 31: 475-479 (1988).
Benfield et al., "Fluoxetine: A Review of Its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Efficacy in Depressive Illness", Drugs 32: 481-508 (1986).
Fuller and Snoddy, "Fluoxetine Enantiomers as Antagonists of .notgreaterthan.-Chloroamphetamine Effects in Rats", Pharmacology Biochemistry & Behavior, 24: 281-284 (1986).
Scrip's New Product Review, No. 7, pp. 13-14 (1986).
Wong et al., "Inhibition of Serotonin Uptake by Optical Isomers of Fluoxetine", Drug Development Research, 6: 397-403 (1985).
Bremner, "Fluoxetine in Depressed Patients: A Comparion with Imipramine", J. Clin. Psychiatry, 45(10): 414-420 (1984).
Power-Smith, "Beneficial Sexual Side-effects from Fluoxetine," Brit. J. Psychiatry 164: 249-250 (1994).
Saper et al., "Double-Blind Trial of Fluoxetine: Chronic Daily Headache and Migraine," Headache 34: 497-502 (1994).
Stevens et al., "Interaction of the Enantiomers of Fluoxetine and Norfluoxetine with Human Liver Cytochromes P450," J. Pharmacology & Experimental Therapeutics 226(7): 964-971 (1993).
Adly et al., "Fluoxetine Prophylaxis of Migraine," Headache 32: 101-104 (1992).
Bergstrom et al., "Quantification and Mechanism of the Fluoxetine and Tricyclic Antidepressant Interaction," Clin Pharmacol. Ther. 51: 239-248 (1992).
Physicians Desk Reference, pp. 905-908, 44th Ed., Medical Economics Data Production Co., N.J. (1990).
Barberich Timothy J.
Teicher Martin H.
Young James W.
Criares Theodore J.
Sepracor Inc.
LandOfFree
Methods for treating depression and other disorders using optica does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating depression and other disorders using optica, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating depression and other disorders using optica will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1492706